Zhifei Biological Submits Clinical Trial Application in China for Nasal Spray Recombinant RSV Vaccine Based on Chimpanzee Adenovirus Vector
Zhifei Biological (SHE: 300122) announced that it has submitted a clinical trial application in China...
Company
Keymed Biosciences’ Bispecific Antibody CM512 Achieves All Endpoints in Phase 2 Trial for Chronic Rhinosinusitis With Nasal Polyps
Keymed Biosciences Inc. (HKG: 2162) announced that the Phase 2 trial of CM512 injection, a...
Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to USD 1.32 Billion, Gaining First‑in‑Class KCNT1 Ion Channel Inhibitor ABS‑1230 for Ultra‑Rare Epilepsy
Jazz Pharmaceuticals (NASDAQ: JAZZ) announced that it will acquire Actio Biosciences, a privately held biopharmaceutical...
CSPC Pharmaceutical Group’s Monkeypox mRNA Vaccine SYS6037 Receives FDA Approval to Conduct Clinical Trials in the US
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its Category 1 preventive biologic product SYS6037...
Novo Nordisk Names AWS Preferred Cloud Provider and Strategic AI Partner to Accelerate Drug Discovery With Agentic AI
Novo Nordisk (NYSE: NVO) and Amazon Web Services (AWS) announced a strategic partnership to accelerate...
Xbiome and BioMap Sign Strategic Cooperation Agreement to Advance AI‑Powered Microbiome Drug and Probiotic Product R&D
Xbiome, a China‑based AI‑driven microbiome drug development company, and BioMap officially signed a strategic cooperation...
BeOne Medicines and Revolution Medicines Announce Clinical Collaboration and Regional Licensing Deal on RAS(ON) Inhibitors Across Select Asian Markets
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced a multifaceted collaboration agreement with...
BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that Imdelltra (tarlatamab for injection)...
Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced a collaboration with TwinEdge Bioscience, a cutting‑edge...
Astellas Submits NDA in Japan for Fezolinetant, a First-in-Class Nonhormonal NK3 Receptor Antagonist for Menopausal Vasomotor Symptoms
Astellas Pharma Inc. (TYO: 4503) announced that it has submitted a New Drug Application (NDA)...
Xtalpi and Gan & Lee Pharmaceuticals’ AI Peptide Delivery Lab Recognized as Beijing Key Laboratory, Deepening AI‑Powered Peptide Drug R&D Collaboration
XtalPi Inc. (HKG: 2228) and Gan & Lee Pharmaceuticals (SHA: 603087) announced that their jointly...
Tonghua Golden‑Horse Unit Signs M&A Intent Agreement to Acquire Controlling Stake in 8PLUS1 Pharma
Guilin Golden-Horse Innovation Investment Co., Ltd., a wholly owned subsidiary of Tonghua Golden-Horse Pharmaceutical Industry...
Xinno Biotechnology and Statia Biopharma Sign Exclusive Deal to Develop STA528 Transdermal Therapy for Autoimmune Diseases
Xinno Biotechnology (Jiashan) Co., Ltd. announced an exclusive technology collaboration agreement with US‑based Statia Biopharma,...
Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System
Sino Medical Sciences Technology Inc. (SHA: 688108) announced that the COMETIU self‑expanding intracranial drug‑eluting stent...
Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01
Hopstem Biotechnology announced the completion of the first close of its nearly RMB 200 million...
Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend
Huadong Medicine (SHE: 000963) announced that KIO015 — a novel, patented carboxymethyl chitosan solution for...
Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance
Recursion (NASDAQ: RXRX) and Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY), together with its subsidiary...
Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao
Kelun-Biotech (HKG: 6990) announced a strategic commercialization agreement with New Frontier Health Technology, a subsidiary...
GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled
GenFleet Therapeutics (HKG: 2595) announced that “Kylin‑Flight 01,” the registrational Phase 3 clinical trial of...
Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor
Braveheart Bio (NASDAQ: BRVE), a partner of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG:...